Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.38 |
| ▸ | IL2 | P60568 | 7/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017256 | 0.92 | SCN9A (0.40) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL16017239 | 0.91 | STIM1 (0.44) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL16017274 | 0.87 | NPC1 (0.50) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL16018233 | 0.87 | STIM1 (0.48) | SCN9ASTIM1ORAI1IL2ORAI2 | |
| SCHEMBL16019810 | 0.84 | CYP1A2 (0.43) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL16017237 | 0.83 | STIM1 (0.44) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL14887768 | 0.80 | TP53 (0.40) | SCN9ASTIM1ORAI1IL2ADORA3 | |
| SCHEMBL14887381 | 0.80 | IL2 (0.56) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL16017284 | 0.80 | STIM1 (0.40) | SCN9ANPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL16018182 | 0.79 | STIM1 (0.48) | SCN9ASTIM1ORAI1IL2ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | SCN9A 235/4885NPC1 262/4885RAB9A 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.